ANTINORI , A

Last name: ANTINORI

First name: A

2020 (v1)

Publication

Metadata-only

Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <=50 copies/ml: does eGFR matter?

Vergori, A Gagliardini, R Gianotti, N

No description

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons

Guaraldi, G Marcotullio, S Maserati, R

This article deals with the attempt to join HIV and geriatric care management in the 2017 edition of the Italian guidelines for the use of antiretrovirals and the diagnostic-clinical management of HIV-1 infected persons.

Uploaded on: April 14, 2023
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024
2024 (v1)

Publication

Metadata-only

Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

d'Arminio Monforte, Antonella Tavelli, Alessandro Di Biagio, Antonio

Objectives: To assess the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people poorly represented in clinical trials and potentially at higher risk of suboptimal response to ART. Methods: Observational cohort study on persons with HIV (PWH) enrolled in ICONA who started BIC/FTC/TAF as initial therapy or as...

Uploaded on: July 3, 2024

ANTINORI , A

Recent uploads